Carl Zeiss Meditec Grew First-Half Revenue for 2018


JENA, Germany—Carl Zeiss Meditec AG xperienced solid growth for the six months ended March 31, 2018, partly due to the strong performance of its Microsurgery strategic business unit. The company reported that despite negative currency effects, revenue grew to €613.7 million, an increase of 4.5 percent from year ago, or 9.5 percent adjusted for currency effects. Adjusted earnings before interest and taxes (EBIT) amounted to around €90 million versus €89.1 million the prior year. The adjusted EBIT margin was 14.7 percent compared with 15.2 percent year ago.

“Our business achieved significant organic growth in the first six months; we are winning market shares in both strategic business units,” commented Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec. “We are satisfied with the development of both the equipment business and recurring sales.”

The Ophthalmic Devices strategic business unit generated €449.3 million in revenue for the six-month period, up 3.7 percent from year ago, or 8.6 percent adjusted for currency effects. The company attributed the increase to both products and solutions in ophthalmic diagnostics, as well as to refractive laser systems and the strong demand for premium and standard intraocular lenses.

Revenue for the company’s Microsurgery strategic business unit rose to €164.4 million, compared with €154.4 million in the same period of the prior year, a 6.5 percent increase, or 12.2 percent with the currency effect. The new products launched on the market in the prior year in neuro and dental surgery performed well.

Carl Zeiss Meditec AG expects revenue to be in a range of €1,230 million to €1,280 million for fiscal year 2017/18. The EBIT margin is expected to be within the range also forecast for the medium term, of 14 percent to 16 percent on an adjusted basis.